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Chronic non-healing wounds, which primarily affect the elderly and diabetic, are
a significant area of clinical unmet need. Unfortunately, current chronic wound
treatments are inadequate, while available pre-clinical models poorly predict the
clinical efficacy of new therapies. Here we describe a high throughput, pre-clinical
model to assess multiple aspects of the human skin repair response. Partial thickness
wounds were created in human ex vivo skin and cultured across a healing time
course. Skin wound biopsies were collected in fixative for the whole-mount staining
procedure. Fixed samples were blocked and incubated in primary antibody, with
detection achieved via fluorescently conjugated secondary antibody. Wounds were
counterstained and imaged via confocal microscopy before calculating percentage
wound closure (re-epithelialization) in each biopsy. Applying this protocol, we reveal
that 2 mm excisional wounds created in healthy donor skin are fully re-epithelialized
by day 4-5 post-wounding. On the contrary, closure rates of diabetic skin wounds
are significantly reduced, accompanied by perturbed barrier reformation. Combining
human skin wounding with a novel whole-mount staining approach allows a rapid
and reproducible method to quantify ex vivo wound repair. Collectively, this protocol
provides a valuable human platform to evaluate the effectiveness of potential wound
therapies, transforming pre-clinical testing and validation.
Introduction
Chronic, non-healing wounds, which are highly prevalent
in the elderly and diabetic, are a majorly unappreciated
area of clinical unmet need. These wounds present a major
physical and psychological burden to patients and cost
healthcare providers billions each year to treat1 . Despite
improved understanding of wound biology and advancements
in technology, up to 40% of chronic wounds still fail to heal
following best standard care2 . Thus, 14-26% of patients with
diabetic foot ulcers subsequently require amputation3 , while
5-year post-amputation mortality rate stands at approximately
70%4 . As a result, there is an urgent requirement to develop
efficacious new therapies to improve patient quality of life
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while reducing the substantial healthcare burden imposed by
poor healing wounds. Poorly predictive pre-clinical models
remain a significant hurdle to the development of effective
new therapies.
Wound repair is a dynamic and multifaceted process
involving a diverse range of cell types, countless levels of
communication and a tissue environment that is temporally
remodeled. Skin healing is underpinned by four major
reparative stages: hemostasis, inflammation, proliferation,
and matrix remodeling. These stages ultimately act to
prevent blood loss and infection, close the wound surface (a
process termed re-epithelialization) and return the skin to an
uninjured state5 . Chronic wounds are associated with diverse
etiology and widespread perturbation to healing processes6 ,
further complicating the identification of therapeutic targets.
Nevertheless, a broad range of models have been developed
to both elucidate the molecular and cellular drivers of wound
pathology and test new therapeutic approaches7 .
The most used wound repair model is acute wounding in
the mouse. Mice are highly tractable for mechanistic studies
and provide validated models of ageing and diabetes8 .
Despite the general similarities shown amongst mouse
and human healing, between-species differences in skin
structure and healing dynamics remain. This means most
murine wound research does not easily translate to the
clinic9 . Consequently, there has been a push towards human
in vitro and ex vivo systems with high applicability and
translatability10,11 .
Here we provide an in-depth protocol for performing
partial thickness excisional wounds in ex vivo human
skin. We also outline our whole-mount staining approach
as a highly reproducible method of evaluating ex vivo
human skin healing. We show the trajectory of epidermal
repair (re-epithelialization) and subsequent barrier formation,
evaluating the rate of wound closure in healthy versus
diabetic human skin. Finally, we demonstrate how whole-
mount staining can be adapted for use with a range of
antibodies to assess various aspects of the healing response.
Protocol
Human skin was obtained from patients undergoing
reconstructive surgery at Castle Hill Hospital and Hull
Royal Infirmary (Hull, UK) under full informed, written
patient consent, institutional guidelines, and ethical approval
(LRECs: 17/SC/0220 and 19/NE/0150). Non-diabetic skin
was collected from patients undergoing routine surgery
(mean age = 68). Diabetic skin was selected from donors who
had established type II diabetes and a history of ulceration
(mean age = 81). Samples from surgery were transported
in holding media and processed immediately upon arrival at
the laboratory. All experimental steps using unfixed human
tissue were performed at Biosafety Level-2 (BSL-2) in a class
II laminar flow biosafety cabinet.
1. Preparation of skin culture media and staining
reagents
NOTE: All reagent and consumable details are provided in the
Table of Materials. Ensure all reagents and equipment used
for the processing and culture of human tissue are sterile.
Sterilize instruments prior to the use and decontaminate with
disinfectant following contact with the tissue. Decontaminate
waste products in 1% disinfectant before disposal.
1. Holding media: Supplement high glucose Dulbecco's
Modified Eagle Medium (DMEM) with 2 mM L-glutamine
and 4% (v/v) antibiotic-antimycotic solution.
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2. Hank's balanced salt solution (HBSS) with antibiotics:
Add 4% (v/v) antibiotic-antimycotic solution to HBSS.
Store at 4 °C until use.
3. Dulbecco's phosphate buffered saline (DPBS): Prepare
DPBS by dissolving 9.6 g of DPBS powder per liter of
distilled water (dH2O). Autoclave to sterilize and store at
4 °C until use.
4. Human skin growth media: Supplement high glucose
DMEM with 2 mM L-glutamine, 1% (v/v) antibiotic-
antimycotic solution and 10% (v/v) fetal bovine serum.
Store at 4 °C until use.
5. Skin fixative: To 450 mL of dH2O, add 40 mL of
formaldehyde solution, 10 mL of glacial acetic acid, 4.5 g
of sodium chloride and 0.25 g of alkyltrimethylammonium
bromide. Store at room temperature (RT) and use within
a few days.
 
CAUTION: Fixative is hazardous (irritant and flammable).
Handle with care and dispose of via an appropriate route.
6. Phosphate buffered saline (PBS): Prepare PBS for
whole-mount staining by adding 6 g of sodium chloride
to 100 mL of phosphate buffer solution and 900 mL of
dH2O.
7. Staining wash buffer: Dissolve 0.5% (v/v) Triton X-100 in
PBS.
8. Blocking buffer: Add 0.2% (w/v) sodium azide and 2% (v/
v) animal serum to staining wash buffer. Store at 4 °C for
up to two weeks.
 
NOTE: Block in the serum of the secondary antibody
host species. Sodium azide will prevent bacterial growth
during incubation.
9. DAPI working solution: Prepare a 5 mg/mL stock of 4′,6-
diamidino-2-phenylindole (DAPI) in dimethyl sulfoxide.
Dilute the stock 1:1,000 in staining wash buffer to give a
5 µg/mL DAPI working solution.
10. Peroxidase block: Add 0.3% (v/v) hydrogen peroxide to
staining wash buffer. Store at 4 °C until use. Keep in the
dark to prevent decomposition.
11. ABC-HRP Kit:
1. HRP-conjugated secondary antibody: 1 drop of
biotinylated rabbit anti-goat IgG in 5 mL of staining
buffer. Store at 4 °C for up to two weeks.
 
NOTE: The kit/secondary used will depend on the
host species of the primary antibody.
2. Avidin-biotin complex (ABC) reagent: 2 drops of
reagent A and 2 drops of reagent B in 5 mL
of staining wash buffer. ABC reagent should be
prepared at least 30 min prior to use. Store at 4 °C
for up to two weeks.
12. Peroxidase substrate: 3 drops of reagent 1, 2 drops of
reagent 2, 2 drops of reagent 3 and 2 drops of hydrogen
peroxide in 5 mL of dH2O. Peroxidase substrate should
be freshly prepared immediately before use and cannot
be stored.
2. Preparation of skin for wounding
NOTE: These steps should be performed in a class II laminar
flow biosafety cabinet.
1. Collect the skin in holding media and transport to the
BSL-2 cabinet.
2. Place the skin dermis side down within a 90 mm
sterile Petri dish and remove adipose tissue with sterile
scissors.
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3. Place the skin in a 50 mL tube containing 25 mL of HBSS
with antibiotics for 10 min at RT. Shake intermittently to
remove any residual blood and adipose tissue.
4. Repeat step 2.3 using a new 50 mL tube.
5. Place the skin in a fresh 50 mL tube containing 25 mL
of HBSS, this time without antibiotics for 10 min at RT.
Shake as in step 2.3.
6. Perform a final skin rinse by placing skin in a new tube
with 25 mL of DPBS. The skin is now ready to wound.
3. Creating ex vivo human skin wounds
NOTE: These steps should be performed in a class II laminar
flow biosafety cabinet.
1. Prepare the skin culture dishes prior to wounding. In a
60 mm Petri dish, stack two sterile absorbent pads and
add 4 mL of human skin media via the side of the dish.
Place a sterile nylon filter membrane onto the absorbent
pad stack.
 
NOTE: Skin media can be altered depending on
the required treatment conditions. Up to three wound
explants may be cultured on each stack.
2. Dry the dermal side of the skin on sterile gauze in a 90
mm Petri dish to remove residual DPBS.
 
NOTE: This prevents the skin from sliding around when
wounding.
3. Place the skin dermis side down on a clean 90 mm
Petri dish lid and dab the epidermis dry with fresh sterile
gauze.
 
NOTE: It is easier to wound the skin in a Petri dish lid
than the base. Subsequent work should be carried out
quickly to prevent the skin drying out.
4. Holding the skin taut, press a 2 mm biopsy punch against
the skin and twist gently. Do not punch entirely through
the skin.
 
NOTE: Partial thickness wounds are designed to punch
through the epidermis and partially into the dermis. There
may be donor-to-donor and site-to-site variability in the
force required to create the partial thickness wound.
5. Use curved toothed tissue forceps to pick up each side
of the 2 mm wound and hook curved iris scissors under
the 2 mm wound to cut it out uniformly.
6. Biopsy around the central 2 mm wound using a 6 mm
biopsy punch to create a 6 mm explant with a partial
thickness 2 mm wound in the center.
 
NOTE: A 6 mm biopsy punch may be used to score
the skin to mark out where each 2 mm wound should
be. Take care not to pierce through the tissue entirely.
Create wound explants in a honeycomb pattern to reduce
wastage.
7. Place wound explants epidermis side up on the nylon
filter membrane stack (prepared in step 3.1).
 
NOTE: When handling wound explants, be careful not to
damage the central wound. Use small forceps and pick
up each explant at opposite sides.
8. Incubate wounds at 32-37 °C and 5% CO2 in a humidified
atmosphere (90-95%) for 1-7 days. Replace the media
every 2-3 days.
4. Whole-mount staining of ex vivo wounds
NOTE: This section describes immunofluorescence and
immunoperoxidase staining methods. Mix all reagents well
before use.
1. Fluorescent staining method
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1. Collect wound explants in 1.5 mL microcentrifuge
tubes containing 500 µL of skin fixative and incubate
at 4 °C overnight.
 
NOTE: The fixative used in this protocol works well
for the described antibodies. Optimization will be
required for other antibodies. Tissue fixation longer
than 24 h may lead to over-fixation.
2. The following day remove the fixative and replace
with 1 mL of staining wash buffer. Biopsies can be
stored in staining wash buffer at 4 °C up to 2 weeks
prior to staining.
 
NOTE: For all wash buffer steps, use a serological
pipette or pipette tip, taking care not to damage the
wound.
3. Aspirate the staining wash buffer and perform one
more rinse with 1 mL of staining wash buffer.
4. Calculate the amount of blocking buffer required for
steps 4.1.5-4.1.6 (number of samples x 300 µL =
amount of blocking buffer in µL). Make extra buffer
if required.
5. Add 150 µL of blocking buffer to each sample and
incubate for 1 h at RT. For all staining steps, ensure
each sample is sufficiently covered and that there
are no bubbles covering the biopsy wound surface.
 
NOTE: This step onwards can be performed in 1.5
mL microcentrifuge tubes or in a 48 well plate. If
using a 48 well plate, incubate the wounds face
down in each well.
6. Dilute the primary antibody in the remaining blocking
buffer.
 
NOTE: Anti-mouse keratin 14 (K14) diluted 1:1,000
in blocking buffer works well. Optimize this step for
use with other antibodies or multiple probes.
7. Aspirate the blocking buffer and add 150 µL primary
antibody per well/microcentrifuge tube. Incubate
wound explants in primary antibody at 4 °C
overnight.
8. The next day, aspirate the primary antibody and
rinse in staining wash buffer containing 0.2% sodium
azide for 1 h at RT (500 µL per sample).
9. Perform three more rinsing steps using staining
wash buffer (30 min per wash, 500 µL per sample).
10. Dilute the fluorescently conjugated secondary
antibody in staining wash buffer (e.g., goat anti-
mouse 488 at 1:400 dilution).
11. Calculate the required amount of secondary
antibody (number of samples x 150 µL = amount in
µL).
12. Add 150 µL of secondary antibody to each well/
microcentrifuge tube. Incubate for 1 h at RT. Perform
incubation steps 4.1.10 - 4.1.16 in the dark as the
secondary antibody is light sensitive.
 
NOTE: This step can be performed at 4 °C overnight
if required. Optimize the concentration of secondary
antibody required for adequate signal and limited
background staining.
13. Remove the secondary antibody and perform 3 x
30 min rinses with staining wash buffer (500 µL per
sample).
14. Discard the leftover wash buffer and calculate the
amount of DAPI working solution required (as per
step 4.1.11).
15. Counterstain each explant with 150 µL of DAPI
working solution for 10 min at RT.
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NOTE: DAPI will stain cell nuclei blue. Hoechst dye
can be used as an alternative to DAPI.
16. Perform two final 30 min washes with staining wash
buffer (500 µL per sample). Biopsies can be stored
in staining wash buffer at 4 °C in the dark up to two
weeks prior to imaging.
2. Brightfield staining method.
1. Perform steps 4.1.1 - 4.1.3.
2. Quench endogenous peroxidase activity with
peroxidase block at 4 °C overnight.
 
NOTE: This step is important when using an
HRP-conjugated antibody to reduce non-specific
background staining from the tissue. Highly
vascularized tissue will contain more endogenous
peroxidase activity.
3. Discard the peroxidase block and rinse twice for 30
min in staining wash buffer.
4. Perform steps 4.1.4 - 4.1.8.
 
NOTE: Washes after step 4.1.7 are particularly
important to remove sodium azide from the samples.
If sodium azide is not adequately removed, it
will inactivate the HRP and interfere with staining
detection.
5. Add 150 µL HRP-conjugated secondary antibody
to each well/microcentrifuge tube and incubate
overnight at 4 °C or 1 h at RT.
6. Remove the secondary antibody and perform 3 x 30
min washes in staining wash buffer.
7. Add 150 µL ABC reagent to each well/
microcentrifuge tube and incubate overnight at 4 °C
or 1 hour at RT.
8. Aspirate the ABC reagent and perform 3 x 30 min
washes in staining wash buffer.
9. Add 150 µL peroxidase substrate to one explant and
determine the time required to detect a noticeable
color change.
 
NOTE: Choose a sample where strong staining
is expected. In this case, a red ring to show the
migrating epidermis (K14). 3,3'-diaminobenzidine-4,
or any other appropriate chromogenic substrate,
may be used as a replacement for this peroxidase
substrate.
10. Once a color change is observed, remove the
peroxidase substrate, and replace with 1 mL of
dH2O.
11. Repeat the peroxidase substrate detection for the
other explants, incubating for the time determined in
step 4.2.11.
12. Rinse all explants with 1 mL of dH2O to remove
residual peroxidase substrate. Although explants
may be stored up to one week at 4 °C prior
to imaging, it is better to image them as soon
as possible to prevent leaching of the peroxidase
substrate into the dH2O over time.
5. Imaging and quantification
1. Fluorescent imaging
 
NOTE: Fluorescent imaging is performed using a
confocal laser-scanning microscope. However, an
inverted fluorescent microscope may be sufficient for
acquiring 2D images to quantify wound closure rates.
When selecting secondary antibodies, ensure that the
chosen fluorochromes are compatible with the excitation
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and emission spectra of the microscopy equipment
available.
1. Use a confocal laser-scanning microscope equipped
with a 2.5x, 10x and 20x objective, x-y-z motorized
stage, digital camera, and acquisition software.
Switch on the transmitted light detector (TPMT) to
allow easy visualization of each biopsy and to enable
measurement of total wound closure. Alternatively,
measure each wound via brightfield microscopy
following fluorescence imaging.
2. Place a 60 mm Petri dish base on the imaging
platform and add a thin layer (around 1 mL) of DPBS.
 
NOTE: If too much DPBS is used, the biopsy will
move around during imaging. Alternatively use a 48
well plate if a plate holder is available.
3. Use small tissue forceps to transfer wound explants
from wells/microcentrifuge tubes to the Petri dish
containing DPBS. Place the biopsy wound side
down in the Petri dish.
4. Use the eyepiece and fluorescent lamp to locate and
focus on the wound. If bubbles are trapped under the
sample in the field of view, pick up the wound with
tissue forceps and reposition.
5. Set up the imaging software, ensuring equal pinhole
size between channels for optimum confocality. For
this, check the value of one airy unit for each channel
and select the largest value. Select scan speed,
image quality and averaging.
 
NOTE: The fluorochromes of the conjugated
secondary antibodies and the chosen counterstain
(e.g., DAPI) will dictate the channels required.
6. Switch on the live acquisition software and adjust the
laser power and gain of each channel to the levels
required to visualize staining. Reduce background
noise by increasing the digital offset.
7. Position the wound in the center of the imaging
plane.
 
NOTE: If the wound does not fill the entire image
due to using a smaller objective or creating a larger
wound, take a panel of images and stitch them
together (manually or with a tiling function in the
relevant imaging software).
8. Acquire images of the wound biopsies. Use the
same imaging settings between explants.
 
NOTE: Higher power images will allow assessment
of tissue structures and cellular marker expression
and location.
9. Collect serial Z stacks through the wound, especially
where the tissue is not completely flat against the
Petri dish. Use analysis software to collapse the




NOTE: Brightfield imaging of immunoperoxidase stained
biopsies can be performed in multiple ways.
1. Inverted microscope imaging: Prepare wound
explants for imaging by placing them in a Petri dish/
well as described in steps 5.1.2-5.1.3. Acquire digital
images under brightfield illumination on an inverted
microscope equipped with a digital camera. Stitch
together multiple images if required.
2. Wireless digital microscope imaging: Use a wireless
digital microscope connected to a phone or laptop
to obtain high quality images in a cost-effective
manner. Place explants wound side up onto some
tissue and remove any residual dH2O (or staining
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wash buffer) from sample storage. Position the
wound explant in the center of the microscope




NOTE: Percentage wound closure can be quantified
in any software that allows freehand shapes to be
drawn and measured. ImageJ can be used to perform
quantification as follows:
1. Open the image to be quantified in ImageJ software.
2. Use the freehand shape tool to draw around the
outside of the re-epithelialized wound where it meets
the normal skin. Press M (or Analyze | Measure) to
acquire an 'outer' area measurement.
 
NOTE: The re-epithelialized wound tissue texture
differs from normal skin. The images do not need to
be scaled prior to this type of analysis.
3. Use the freehand shape tool to draw around the
open wound area. This is where the open wound
meets the inside edge of the re-epithelializing tissue.
Press M (or Analyze | Measure) to acquire an 'inner'
area measurement.
4. Use the following equation to deduce percentage
wound re-epithelialization/closure:
 
% Closure = (Outer Wound Area - Inner Wound
Area) / (Outer Wound Area) x 100
 
NOTE: Percentage area coverage of antibodies
can be deduced in the same way (e.g.,
K14) or as a percentage of the total wound
area. Percentage intensity can also provide
semi-quantitative information about tissue level
expression of markers of interest, while high power
imaging presents expression data at the cellular
level.
Representative Results
In this report, we present a novel ex vivo skin wounding
and whole-mount staining approach to assess factors that
influence the human skin repair response. Figure 1A shows a
schematic of the procedural pipeline, which can be performed
in 3-10 days, depending on wound incubation times. The
partial thickness wounds are cultured on membrane stacks
at the air : membrane interface and can be collected
for whole-mount staining, embedded in paraffin or OCT
medium for general histology, or frozen in liquid nitrogen
for biochemical analysis (Figure 1B). We generally create
2 mm partial thickness wounds within the center of 6 mm
explants. However, the size of the wound and surrounding
explant may be altered depending on requirements. The
whole-mount procedure has been successfully adapted for
both immunoperoxidase and immunofluorescence staining
methods (Figure 1C).
Immunofluorescence allows for the probing of tissue with
multiple antibodies. For this, we advise using primary
antibodies raised in different species, and species-matched
fluorescently conjugated secondary antibodies to limit cross-
species reactivity. Antibody concentrations and incubation
times will need to be optimized. If background staining
is observed, reduce antibody concentrations, increase
wash steps, and add blocking buffer to the secondary
antibody. Fresh tissue viability can be directly assessed with
commercial viability dyes (see Table of Materials). We also
show that tissue may be fixed post viability staining and
successfully imaged when it is practically suitable (Figure
1D).
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Figure 1: The human ex vivo wounding and whole-mount staining approach. (A) Pipeline depicting the procedural
workflow from collecting skin and performing ex vivo wounding, to staining tissue and analyzing data. (B) Diagram
demonstrating the human ex vivo skin wound culture system with analyses routinely performed on the tissue. (C) Whole-
mount staining can be employed using both immunoperoxidase and immunofluorescence techniques. K14 = keratin 14. (D)
Live tissue may be stained with commercial viability dyes and imaged successfully post fixation. Bar = 100 µm. This staining
was performed in non-diabetic skin. Please click here to view a larger version of this figure.
The most widely applicable use for whole-mount staining
of wounds is to determine wound closure rate in a more
reproducible manner than can be provided via histological
sectioning. Percentage closure was quantified as percentage
re-epithelialization of the wound surface, as demonstrated in
Figure 2A. Percentage area coverage of specific markers can
be measured from the total wound area or as a percentage
of the re-epithelialized wound. We characterized healing in
healthy (non-diabetic) versus diabetic skin across a time
course of seven days, collecting wounds at each day post-
wounding (representative images, Figure 2B). Healthy skin
wounds closed over time as expected, with full closure
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observed in most samples by day 4-5. On the contrary,
diabetic skin wounds failed to close fully within the seven-
day analysis period (Figure 2C). A significant delay in wound
closure was observed between healthy and diabetic skin
wounds when comparing healing rates at each time-point
post-injury (P < 0.001 to day 6, P < 0.05 at day 6 and P < 0.05
to P < 0.001 at day 7).
Following assessment of overall wound closure rates; we
measured the percentage of the entire wound area (outer
area in Figure 2A) where K14 positive cells could be
visualized (green staining in Figure 2B). Interestingly, we
observed that in healthy ex vivo skin wounds, K14 staining
peaked at day 2 and then rapidly declined (significance at
each time-point versus the day 2 peak, Figure 2D). This is
likely reflecting re-formation of the early epidermal barrier,
excluding K14 antibody penetration through differentiated
epidermal layers (see Figure 2E schematic). During the re-
epithelialization process, basal layer (K14+ve) keratinocytes
migrate inwards over the open wound such that the epidermis
closer to the outer wound edge forms earlier than the
epidermis closer to the inner wound edge (migrating front).
While the front edge of the newly formed epidermis continues
to migrate to close the remaining open wound, the outer edge
epidermis begins to differentiate to reform the other epidermal
layers. In early healing, we would thus expect to see most
of the re-epithelialized area consists of basal (K14+ve) cells,
while in later repair K14 staining is lost as the epidermis
differentiates from the outside inwards (see whole-mount
images in Figure 2E). Therefore, the decline in K14 staining
shown in Figure 2D (downward arrows) correlates with
increased epidermal differentiation. Interestingly, visible K14
staining peaked earlier in healthy (day 2) versus diabetic (day
4) wounds, further demonstrating that re-epithelialization and
subsequent epidermal differentiation are delayed in diabetic
skin wounds.
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Figure 2: Whole-mount staining reveals perturbed healing rates in diabetic versus healthy skin. (A) The method used
to quantify wound closure from outer and inner wound measurements. Brightfield images show keratin 14 (K14) staining in
red. Bar = 300 µm. (B) Representative images of healing over time (day post-wounding) in healthy and diabetic skin. Bar =
500 µm. K14 = green. DAPI = blue nuclei. (C) Quantification of wound closure rates (percentage re-epithelialization) showing
that ex vivo wounds from healthy skin close significantly faster than ex vivo wounds from diabetic skin. H = healthy. Db =
diabetic. (D) Percentage K14 staining peaks earlier in healthy versus diabetic skin and then declines in line with increased
epidermal differentiation (down arrows). (E) K14 (basal epidermal cell) staining is lost as the epidermis differentiates. D =
differentiated. ND = not differentiated. White dotted lines depict inner and outer wound edges. White arrows = direction of
migration. n = 6 wounds per donor, per time point. Mean +/- SEM. * = P < 0.05, ** = P < 0.01 and *** = P < 0.001. Healthy
and diabetic compared at each healing time point in C (P value for least significant comparison). Temporal change in K14
staining compared to peak for each donor in D. Please click here to view a larger version of this figure.
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We next used whole-mount staining to explore tissue
expression and localization of other wound-relevant markers
in non-diabetic skin (Figure 3). All antibodies used and
their working concentrations are provided in the Table of
Materials. Blood vessels in the open wound stained positively
with alpha smooth muscle actin (a-SMA) antibody, used in
combination with K14 to delineate the epidermal edges in
lower power images (Figure 3A). The dermal matrix was
stained with antibodies against collagen type I (COL 1) and
fibronectin (Fn). Here collagen was observed as abundant
thick fibers while fibronectin fibers were sparse, wavy, and
thin (Figure 3A). Our whole-mount staining approach is
also able to provide cell level resolution of staining, as
demonstrated for K14-positive keratinocytes (Figure 3B).
Finally, we show that human ex vivo wounds possess resident
immune cells, with Langerhans cells detected around newly
formed epidermis at day 3 post-wounding (Figure 3C).
Indeed, these results suggest that whole-mount staining may
be used to investigate key features of the healing response
including inflammation, proliferation, and the extracellular
matrix (Figure 4A). Taken together, our data reveal that the
combined ex vivo skin wounding and whole-mount staining
procedure is a valid method to assess various aspects of
healthy and diabetic (pathological) human skin repair.
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Figure 3: Optimization of the whole-mount staining approach for use with other antibodies. (A) Blood vessels were
stained with alpha smooth muscle actin (α-SMA, green) and keratin 14 (K14, red), while matrix fibers were stained with
collagen I (COL 1, red) and fibronectin (Fn, green). (B) The whole-mount procedure provides up to cell level resolution of
localization (K14, green; K1, red). (C) CD1a+ve Langerhans cells (green) observed in newly formed epidermis. DAPI =
blue nuclei. Bar = 100 µm. White dotted lines show inner and outer wound edges and separate wound from epidermis. This
staining was performed in non-diabetic skin. Please click here to view a larger version of this figure.
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Figure 4: Validity of the whole-mount staining procedure for assessing wound healing. (A) Illustration depicting how
the whole-mount staining technique can evaluate wound-relevant processes. Antibodies used = red text. K14 = keratin 14.
COL 1 = collagen 1. Fn = fibronectin. (B) The whole-mount staining procedure (blue arrows) introduces less variability to
wound closure measurements than standard histological analysis (red arrows). S1 = section 1. WE = wound edge. Bar = 300
µm. This staining was performed in non-diabetic skin. Please click here to view a larger version of this figure.
Discussion
In this experimental protocol, we describe an optimized
method for evaluating wound closure in human ex vivo
skin using whole-mount tissue staining. This is an important
resource to allow critical evaluation of potential wound
treatments, and to provide better understanding of the
human wound repair response. We have published healing
assessment in ex vivo skin wounds previously12,13 , yet in
these reports the whole-mount staining approach was not
used to measure wound closure. Whole-mount staining is far
easier and requires less technical experience than standard
histology, which involves paraffin or OCT embedding and
sectioning of samples. The whole-mount procedure also
reduces experimental variability, allowing quantification of
the entire wound and not just a single transverse section
at a defined position within the tissue (see Figure 4B for
comparative illustration). We fully support the importance
of quantifying healing of the entire non-symmetrical wound
structure, as clearly outlined by Rhea and Dunnwald
for murine acute wounds14 . These authors showed the
importance of serially sectioning in vivo excisional wounds
for reproducible and precise measurements of wound
morphology. Serial sectioning could equally be applied to
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human ex vivo wounds; however, for accurate quantification
of wound closure and re-epithelialization, high throughput
whole-mount staining should be the preferred method. We
note that this whole-mount staining protocol should also be
compatible with subsequent processing (wax or OCT) for
traditional histological analysis.
Whole-mount staining is not without disadvantages. While it
affords higher reproducibility in wound healing experiments,
it does require the use of more tissue for analysis than
standard histological techniques. This may be an issue where
tissue access is limited, particularly where multiple antibodies
need to be assessed. An alternative approach would be to
employ an incisional wounding method where wound width
is relatively uniform and variability is reduced (as shown
in mouse and human wounds15,16 ). However, excisional
wounds remain more applicable to most pathological wound
types17 .
In this study, 2 mm partial thickness wounds were created
within the center of 6 mm skin explants. This method may be
optimized for alternative excisional wound and explant sizes
at different skin depths18 . In addition, the force required to
generate wounds will vary between donors, where aged skin
will require less force to biopsy. We would also avoid using
skin displaying prominent stretch marks or other structural
alterations. We have validated a range of antibodies to
consider different aspects of the ex vivo healing response.
This protocol may also be used with other skin-relevant
antibodies, where antibody concentrations and incubation
times will need to be optimized. Nevertheless, we believe
our protocol is most suited to absolute quantification of
total wound closure, followed by spatial assessment of
specific proteins of interest. While whole-mount provides
reduced resolution of immunolocalization versus standard
histological analysis of tissue sections, it provides additional
3D information that is missing from standard 2D histology.
One caveat of assessing healing in ex vivo skin versus
in vivo models is that it lacks a systemic response. An
important aspect of wound repair is inflammation and
subsequent tissue granulation, which is caused by an
influx of inflammatory cells and endothelial cells from the
vasculature19 . Despite this limitation, ex vivo skin still
provides a better recapitulation of clinical healing than
cell-based wound assays. In vitro experiments in general
involve single cell type monolayers or co-cultures grown
on tissue culture plastic, whereas ex vivo skin provides a
native environment to explore cell behavior. More recently,
a number of skin equivalent systems have emerged, where
skin is grown in a laboratory setting from artificial matrix
and isolated skin cells20,21 . Although these models mimic
human skin better than most in vitro approaches, they still
do not fully simulate the native tissue environment and
are generally too fragile to injure reproducibly. Additionally,
we (and others) have demonstrated that ex vivo human
skin tissue retains resident immune cells, which will no
doubt contribute to repair22,23 . Future work should now
focus on extending the viability and immunocompetency
of the ex vivo model for late-stage healing assessment24 .
One option is further advancement of promising organ-on-a-
chip technologies capable of prolonging tissue viability and
maintaining native skin architecture for up to two weeks in
culture25 . Ex vivo models have also begun to consider the
importance of the skin inflammatory response by successfully
incorporating immune cells, such as neutrophils, into the host
tissue26  or injecting host tissue with antibodies to elicit an
immune reaction27 . We expect that these findings will pave
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the way for development of more refined and translatable
methods in the future.
A major benefit of using ex vivo skin to measure wound
closure is the ability to compare healing rates in healthy
(e.g., non-diabetic) versus pathological (e.g., diabetic or
aged) tissue. Here we showed that re-epithelialization and
barrier formation are indeed impaired in diabetic versus
healthy ex vivo wounds. Indeed, this provides a route for
pre-clinical assessment of pathological repair, where ageing
and diabetes are major risk factors for developing chronic
wounds1 . While in vitro pathological models exist, such as
cells isolated from aged and diabetic tissue, or cells cultured
in high glucose to mimic hyperglycemia28,29 , these cells can
quickly lose their phenotype once removed from the in vivo
microenvironment. An important component of the extrinsic
pathological healing environment is the dermal matrix, which
is altered in both ageing and diabetes30 . Indeed, this
perturbed matrix affects the behavior of resident and naïve
fibroblasts31,32 . Thus, the importance of studying cells in
their host tissue environment cannot be underestimated.
In summary, our protocol provides an important platform to
quantify human wound re-epithelialization, explore regulatory
factors and to test the validity and efficacy of potential
therapeutics12,13 . While pre-clinical testing does still require
in vivo approaches, a combined strategy using ex vivo human
tissue and in vivo murine wounding should refine the pre-
clinical pathway, reducing animal use while increasing cross-
species translatability.
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